RxDoctor Payments Data

Cynthia Konz, MD

Internal Medicine · Dubuque, IANPI 1013986918

Payments from drug & device makers

$532in general payments, 2019–2025

Across 30 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$115
  • AbbVie$73
  • Amgen$57
  • Astellas Pharma US Inc$45
  • Pfizer$42
  • GSK$36
  • plus $164 from 9 others

What the payments were for

  • Food & beverage$532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$532 in reported general payments places this provider in the 75th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$224,252
Medicare patients
348
Services billed
7,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$150,953
JanuviaSitagliptin Phosphate85$79,974
JardianceEmpagliflozin50$68,663
RybelsusSemaglutide29$45,038
XareltoRivaroxaban28$38,233
MyrbetriqMirabegron59$35,016
Bydureon BciseExenatide Microspheres20$16,538
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,342
MounjaroTirzepatide15$15,521
Repatha SyringeEvolocumab18$14,052
Potassium Chloride396$12,079
FarxigaDapagliflozin Propanediol20$11,604
Spiriva RespimatTiotropium Bromide18$10,814
Atorvastatin Calcium956$9,109
Gabapentin342$5,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$150,953208 claims
Boehringer IngelheimJardiance, Spiriva Respimat$11$79,47668 claims
Novo NordiskRybelsus$115$45,03829 claims
Johnson & JohnsonXarelto$27$38,23328 claims
Astellas Pharma US IncMyrbetriq$45$35,01659 claims
GSKTrelegy Ellipta$36$16,34221 claims
AstraZenecaFarxiga$33$11,60420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →